• OPEN AN ACCOUNT
Indian Indices
Sensex
83,021.75 989.94
( 1.21%)
Global Indices
Nasdaq
50,205.66 -574.76
(-1.13%)
Dow Jones
7,342.05 -19.48
(-0.26%)
Hang Seng
59,472.71 448.43
(0.76%)
Nikkei 225
10,468.58 -82.59
(-0.78%)
Forex
USD-INR
93.54 -0.42
(-0.44%)
EUR-INR
102.90 -0.55
(-0.53%)
GBP-INR
123.45 -0.54
(-0.44%)
JPY-INR
0.59 0.00
(-0.28%)

EQUITY - MARKET SCREENER

Kanel Industries Ltd
Industry :  Trading
BSE Code
ISIN Demat
Book Value()
500236
INE252C01023
8.6013936
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
KANELOIL
0
100.85
EPS(TTM)
Face Value()
Div & Yield %
0
10
0
 

Shilpa Medicare secures CDSCO approval for launch of OERIS™ in India
Sep 11,2026

Shilpa Medicare announced that the Subject Expert Committee (SEC) under the Central Drugs Standard Control Organization (CDSCO) has issued final approval for grant of marketing authorization for OERIS™ (Ondansetron Extended-Release Injection, 100 mg/mL).

OERIS™ is designed to be the world's first extended-release ondansetron injectable formulation, providing sustained antiemetic action for up to 120 hours (5 days) following a single administration – a first-of-its-kind approval in both India and globally.

OERIS™ will be launched in India and enjoys patent protection in India until 2039. OERIS® is designed to be the world's first extended-release ondansetron injectable formulation providing sustained antiemetic protection for up to 120 hours (5 days) following a single administration.